Literature DB >> 1505080

Changes in serum lipids and lipoproteins in cancer patients during chemotherapy.

C G Alexopoulos1, S Pournaras, M Vaslamatzis, A Avgerinos, S Raptis.   

Abstract

We studied serum lipid and lipoprotein changes occurring during chemotherapy in 57 patients with chemosensitive cancers, including 18 malignant lymphomas, 18 breast carcinomas, 14 small-cell lung carcinomas, and 7 urothelial-cell carcinomas. Patients who responded favorably to chemotherapy demonstrated a significant increase in serum total cholesterol and LDL cholesterol values, with the singular exception of breast-cancer patients, who exhibited a nonsignificant decrease in both of these parameters. Serum levels of free cholesterol and HDL cholesterol did not show any significant changes. Finally, serum triglycerides tended to increase after effective chemotherapy, but this was of statistical significance only in breast-cancer patients. Although our findings were based on a rather small number of patients, they indicate that the lipid and lipoprotein disorders reported in cancer patients are reversible by effective treatment of the tumor, suggesting that these disorders are a secondary phenomenon of malignancy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1505080     DOI: 10.1007/bf00689971

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  9 in total

1.  Stimulation of low density lipoprotein receptor activity by conditioned medium from a human cancer cell line.

Authors:  O Shiroeda; N Yamaguchi; K Kawai
Journal:  Cancer Res       Date:  1987-09-01       Impact factor: 12.701

2.  Colon cancer and blood-cholesterol.

Authors:  G Rose; H Blackburn; A Keys; H L Taylor; W B Kannel; O Paul; D D Reid; J Stamler
Journal:  Lancet       Date:  1974-02-09       Impact factor: 79.321

3.  The relationship of serum cholesterol to the incidence of cancer in Evans County, Georgia.

Authors:  J D Kark; A H Smith; C G Hames
Journal:  J Chronic Dis       Date:  1980

4.  Hypocholesterolaemia in malignancy due to elevated low-density-lipoprotein-receptor activity in tumour cells: evidence from studies in patients with leukaemia.

Authors:  S Vitols; G Gahrton; M Björkholm; C Peterson
Journal:  Lancet       Date:  1985-11-23       Impact factor: 79.321

5.  Serum lipids and lipoprotein disorders in cancer patients.

Authors:  C G Alexopoulos; B Blatsios; A Avgerinos
Journal:  Cancer       Date:  1987-12-15       Impact factor: 6.860

6.  Cholesterol and mortality in New Zealand Maoris.

Authors:  R Beaglehole; M A Foulkes; I A Prior; E F Eyles
Journal:  Br Med J       Date:  1980-02-02

7.  Total serum cholesterol and cancer mortality in a middle-aged male population.

Authors:  F Cambien; P Ducimetiere; J Richard
Journal:  Am J Epidemiol       Date:  1980-09       Impact factor: 4.897

8.  Hypocholesterolaemic factor from gallbladder cancer cells.

Authors:  Y Ueyama; Y Matsuzawa; S Yamashita; T Funahashi; N Sakai; T Nakamura; M Kubo; S Tarui
Journal:  Lancet       Date:  1990-09-22       Impact factor: 79.321

9.  Plasma lipids and mortality: a source of error.

Authors:  G Rose; M J Shipley
Journal:  Lancet       Date:  1980-03-08       Impact factor: 79.321

  9 in total
  23 in total

1.  Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment.

Authors:  May A Beydoun; Lori L Beason-Held; Melissa H Kitner-Triolo; Hind A Beydoun; Luigi Ferrucci; Susan M Resnick; Alan B Zonderman
Journal:  J Epidemiol Community Health       Date:  2010-09-14       Impact factor: 3.710

2.  Impaired cholesterol esterification in the plasma in patients with breast cancer.

Authors:  P V Subbaiah; M Liu; T R Witt
Journal:  Lipids       Date:  1997-02       Impact factor: 1.880

Review 3.  Role for TNF in atherosclerosis? Lessons from autoimmune disease.

Authors:  Gayle E McKellar; David W McCarey; Naveed Sattar; Iain B McInnes
Journal:  Nat Rev Cardiol       Date:  2009-06       Impact factor: 32.419

4.  Plasma changes in breast cancer patients during endocrine therapy--lipid measurements and nuclear magnetic resonance (NMR) spectroscopy.

Authors:  T Engan; J Krane; D C Johannessen; P E Lønning; S Kvinnsland
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

Review 5.  Clinically Relevant Physical Benefits of Exercise Interventions in Breast Cancer Survivors.

Authors:  Amy A Kirkham; Kelcey A Bland; Sarah Sayyari; Kristin L Campbell; Margot K Davis
Journal:  Curr Oncol Rep       Date:  2016-02       Impact factor: 5.075

Review 6.  Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment.

Authors:  Ernest Choy; Kandeepan Ganeshalingam; Anne Grete Semb; Zoltán Szekanecz; Michael Nurmohamed
Journal:  Rheumatology (Oxford)       Date:  2014-06-06       Impact factor: 7.580

Review 7.  Exercise Prevention of Cardiovascular Disease in Breast Cancer Survivors.

Authors:  Amy A Kirkham; Margot K Davis
Journal:  J Oncol       Date:  2015-08-03       Impact factor: 4.375

8.  Altered lipid levels in untreated patients with early polymyositis.

Authors:  Han Wang; Yingying Cai; Lin Cai; Yingchun Hu; Xianxiang Chen; Juelin Deng
Journal:  PLoS One       Date:  2014-02-24       Impact factor: 3.240

9.  Chemotherapy Agents Alter Plasma Lipids in Breast Cancer Patients and Show Differential Effects on Lipid Metabolism Genes in Liver Cells.

Authors:  Monika Sharma; Jo Tuaine; Blair McLaren; Debra L Waters; Katherine Black; Lynnette M Jones; Sally P A McCormick
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

10.  Pretreatment TG/HDL-C Ratio Is Superior to Triacylglycerol Level as an Independent Prognostic Factor for the Survival of Triple Negative Breast Cancer Patients.

Authors:  Danian Dai; Bo Chen; Bin Wang; Hailin Tang; Xing Li; Zhiping Zhao; Xuan Li; Xiaoming Xie; Weidong Wei
Journal:  J Cancer       Date:  2016-08-07       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.